GLOBAL DISPARITIES IN GENETIC TESTING ACCESS
“๐๐ญ๐ฟ๐ช๐ท๐ฌ๐ฎ๐ญ ๐ฐ๐ฎ๐ท๐ฎ๐ฝ๐ฒ๐ฌ ๐ฝ๐ธ๐ธ๐ต๐ผ ๐ช๐ป๐ฎ ๐น๐ธ๐๐ฎ๐ป๐ฏ๐พ๐ต, ๐ซ๐พ๐ฝ ๐ฒ๐ฏ ๐ช๐ฌ๐ฌ๐ฎ๐ผ๐ผ ๐ฒ๐ผ ๐ต๐ฒ๐ถ๐ฒ๐ฝ๐ฎ๐ญ ๐ฝ๐ธ ๐๐ฎ๐ช๐ต๐ฝ๐ฑ๐ ๐ท๐ช๐ฝ๐ฒ๐ธ๐ท๐ผ, ๐ฝ๐ฑ๐ฎ ๐น๐ป๐ธ๐ถ๐ฒ๐ผ๐ฎ ๐ธ๐ฏ ๐น๐ป๐ฎ๐ฌ๐ฒ๐ผ๐ฒ๐ธ๐ท ๐ถ๐ฎ๐ญ๐ฒ๐ฌ๐ฒ๐ท๐ฎ ๐ซ๐ฎ๐ฌ๐ธ๐ถ๐ฎ๐ผ ๐ช ๐น๐ป๐ฒ๐ฟ๐ฒ๐ต๐ฎ๐ฐ๐ฎ, ๐ท๐ธ๐ฝ ๐ช ๐ป๐ฒ๐ฐ๐ฑ๐ฝ.” – Prof. Fatima Bosch
๐งฌ In recent years, rapid advancements in genomic technologies have redefined healthcare, offering deep insights into disease prevention, diagnosis, & treatment. Genetic testing; a linchpin of precision medicine, enables the detection of inherited conditions & disease predispositions. But while its benefits are immense, access to these tools remains deeply unequal across the globe.
๐น Genetic testing access is shaped by intertwisted socioeconomic, geographic, & cultural barriers. High-income countries benefit from strong healthcare systems & expertise, while LMICs often face shortages in resources, personnel, & lab capacity. Access also varies within countries, with rural areas experiencing delays due to limited facilities and distance. Cultural stigmas, fear of discrimination, & low awareness further hinder testing uptake globally.
๐น The effects are serious:
➡️ Delayed or missed diagnoses, especially for treatable hereditary conditions,
➡️ Higher morbidity & mortality in underserved or marginalized populations,
➡️ Exclusion from genomic research, skewing data & limiting the relevance of emerging therapies for diverse populations. For instance, underrepresented ethnic groups may harbor unique genetic variants. When excluded from studies, the treatments developed often fail to address their specific needs, widening health disparities.
๐น Addressing disparities needs coordinated, multi-sectoral action. Governments & global bodies should subsidize genetic testing in LMICs. Partnerships can improve infrastructure & equity. Digital tools & mail-in kits reduce geographic barriers. Public campaigns must demystify testing and highlight its preventive value. Engaging community leaders fosters trust. Funders must support research on underrepresented groups to ensure precision medicine benefits all.
⚠️ In an Oystershell, the bottom line genetic testing holds enormous potential; but without equity in access, its promise remains unrealized for much of the world. Overcoming this imbalance is not just a scientific or technical challenge. It’s a matter of justice. By closing these gaps, we can move toward a future where genetic insight is a universal right, not a luxury.
Abubakar Abubakar ✍๐ป
• Weng, Patricia L. et al. The American Journal of Human Genetics, Volume 108, Issue 2, 357 - 367.
• Martin, A.R., Kanai, M., Kamatani, Y. et al. Nat Genet 51, 584–591 (2019).
• Chansavang, A., Maalej, S., Narjoz, C., Loriot, M. A., & Pallet, N. (2020). Pharmacogenomics, 21(17), 1217–1226.
#GeneticTesting #HealthEquity #SocialJustice #PublicHealth #GeneticCounseling #Genomics #PrecisionMedicine #ART ๐
Comments
Post a Comment